Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by knoxton Dec 09, 2021 8:52am
589 Views
Post# 34213815

Up date on news

Up date on news
Theralase Technologies Expands Intellectual Property Portfolio

 

09 Dec 202108:19 ET  

 

08:19 AM EST, 12/09/2021 (MT Newswires) -- Theralase Technologies (TLT.V), a clinical stage pharmaceutical company trading near 52 week highs, on Thursday announced the expansion of its Intellectual Property (IP) portfolio.

Theralase was recently granted an Indian patent which covers numerous Theralase photo dynamic compounds destined for the Indian market. These include TLD-1433 which is currently under clinical investigation in a Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study in Canada and the United States.

Arkady Mandel, Interim CEO and Chief Scientific Officer, said: "This patent is strategic to opening up new international opportunities for Theralase by expanding its IP portfolio of medical laser and oncology focused technologies internationally."


<< Previous
Bullboard Posts
Next >>